pharmaphorum

JUNE 12, 2025

Importantly, this type of insight also supports smarter negotiations around drug pricing. In communities where there is only one pharmacy – or none – there is no competition to drive down prices. By identifying these regions, PBMs can better advocate for fair pricing models that reflect real-world access challenges.

Health and Personal Care Stores 59

Health and Personal Care Stores Diabetes Pharmaceutical Companies Pharmaceutical Companies 59

Pharmaceutical Commerce

JUNE 17, 2025

AI in value-based pricing and RWE generation AI has the potential to transform value-based pricing (VBP) by leveraging machine learning for dynamic pricing models that adjust drug prices based on real-world patient outcomes.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 52

Pharmacy Times

JUNE 23, 2025

This pathway’s expanded use and shifting Centers for Medicare & Medicaid Services (CMS) policies are reshaping reimbursement practices and therapeutic equivalence standards for 505(b)(2) drugs.

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Dosage Hospitals 26

Pharmacy Times

JUNE 16, 2025

According to Trump, patients could see cost reductions of 30% to 80%, but experts question the feasibility and practicality of implementing such a policy within the complex United States drug pricing and supply system. Kennedy Jr, is permitted to develop a new rule that ties American drug prices to those of other nations.

Pharmacy Technician 26

Pharmacy Technician Drug Pricing Insurance Coverage and Processing Compounding Pharmacies 26

Pharma Marketing Network

MAY 11, 2025

accelerates its crackdown on drug pricing through new legislation and regulatory enforcement, pharma companies in China, India, Japan, and South Korea are feeling the ripple effect. This move marked a major shift in how drug pricing is managed in the United Statesa market that contributes significantly to global pharma revenues.

Drug Pricing 59

Drug Pricing Biosimilars Communication Pharmaceutical Companies 59

Pharmaceutical Commerce

JUNE 17, 2025

How Recent Executive Orders Impact the Drug Pricing Landscape Nicholas Saraceno, Editor May 30th 2025 Podcast Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.

Health and Personal Care Stores 52

Health and Personal Care Stores Insurance Coverage and Processing Hospitals Drug Pricing 52

Pharmaceutical Technology

JULY 1, 2025

Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence. Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence.

Packaging 52

Packaging Drug Development Chemotherapy Biosimilars 52

Pharmaceutical Commerce

JUNE 16, 2025

Final thoughts Budget cuts may be coming, driven by drug pricing changes or economic pressures. Build in the ability to track key metrics such as time to therapy, abandonment rates, and financial impact of hub performance. Be ready to defend your hub by showing how it directly improves prescription lift, fills, and patient adherence.

Insurance Coverage and Processing 52

Insurance Coverage and Processing Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 52

PhRMA

JUNE 27, 2025

Yesterday, PhRMA submitted comments in response to the Centers for Medicare & Medicaid Services (CMS) draft guidance for implementation of the prescription drug price-setting program established under the Inflation Reduction Act (IRA).

Drug Pricing 52

Drug Pricing 52

Pharmaceutical Technology

JULY 7, 2025

How will RFK Jr’s American dream for vaccines play out?

Packaging 122

Packaging Communication Hospitals Drug Pricing 122

Pharmaceutical Technology

JULY 2, 2025

Trikafta, known under the brand name Kaftrio in Europe, is the best-selling cystic fibrosis drug in the world, generating revenue of $11.02bn in 2024. Kaftrio loses patient protection in 2037, at which point biosimilars are set to enter the market. Historically, this erodes the market dominance held by the branded drug.

Packaging 52

Packaging Communication Hospitals Drug Pricing 52

Pharmaceutical Technology

JULY 4, 2025

Biosimilars and generics flood the market upon patent loss, which exerts pricing pressure on the branded product. There has been a push by the Trump administration to increase biosimilar and generic drug use in the US. Biosimilars and generics can be as much as 80% cheaper than branded alternatives.

Biosimilars 52

Biosimilars Chemotherapy Packaging Communication 52

Pharmacy Times

JUNE 12, 2025

Trump signed an executive order titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” with the objective of lowering drug prices, namely on branded drug products, for American consumers. How Does Drug Pricing in the US Compare With Other Countries? REFERENCES 1.

Pharmacy Technician 26

Pharmacy Technician Community Pharmacies Drug Pricing Hospitals 26

Pharmaceutical Technology

JULY 7, 2025

How will RFK Jr’s American dream for vaccines play out?

Hospitals 52

Hospitals Insurance Coverage and Processing Packaging Communication 52

Pharmaceutical Technology

JULY 7, 2025

How will RFK Jr’s American dream for vaccines play out?

Packaging 52

Packaging Drug Development Drug Pricing Biosimilars 52

pharmaphorum

JUNE 17, 2025

. … So if we can reduce some of the unnecessary cost and time of the six to 15 months toxicity and animal testing period, we can lower barriers to entry, we can lower R&D costs, and we can ideally lower drug prices, which is a big goal for this administration.”

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 52

Pharmaceutical Technology

JULY 10, 2025

Sectors Sections Clinical Trials Drug Manufacturers Therapy Area Pricing and Market Access Latest E. The partnership will enhance the availability of the affordable biosimilar on a global scale. The biosimilar is a recombinant humanised antibody Fab’ fragment targeting TNFα, conjugated to a 40kDa polyethylene glycol.

Biosimilars 52

Biosimilars Packaging Hospitals Communication 52

Pharmaceutical Commerce

JUNE 13, 2025

The Trump Administration has revived the most-favored nation (MFN) drug pricing model as a seven-year test, which would tie US drug prices to the lowest prices paid by certain OECD countries—an approach previously blocked by courts. Concerns over price controls. What is MFN model pricing? China wins?

Drug Pricing 59

Drug Pricing Biosimilars Pharmaceutical Companies Pharmaceutical Companies 59

Pharmaceutical Technology

JULY 4, 2025

Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marketing authorisation in the European Union (EU). The drug addresses bone loss due to hormone ablation therapy in men with prostate cancer and is used in long-term systemic glucocorticoid therapy in adults.

Biosimilars 52

Biosimilars Chemotherapy Packaging Communication 52

Pharmaceutical Technology

JULY 7, 2025

How will RFK Jr’s American dream for vaccines play out?

Packaging 52

Packaging Adverse Reactions Communication Hospitals 52

Pharmaceutical Technology

JULY 11, 2025

Go deeper with GlobalData Reports LOA and PTSR Model - Bevacizumab Biosimilar in Endometrial Cancer Reports LOA and PTSR Model - Iparomlimab + Tuvonralimab in Nasopharyngeal C. How will RFK Jr’s American dream for vaccines play out? Data Insights The gold standard of business intelligence. Find out more Sign up for our daily news round-up!

Packaging 52

Packaging Hospitals Biosimilars Communication 52

Big Molecule Watch

MAY 15, 2025

In the past month, President Trump signed two executive orders concerning drug access and affordability, including for biologics and biosimilar drugs. 14273 (EO 273), titled Lowering Drug Prices By Once Again Putting Americans First. discounts on prices and the manufacturers that acquiesce to these price demands.

Drug Pricing 59

Drug Pricing Biosimilars Pharmaceutical Manufacturing 59

FDA Law Blog: Biosimilars

MAY 15, 2025

Gaulkins presentation, Product Price Increases: A SPTR Practical Walkthrough , will provide an interactive case study outlining the hypothetical enforcement, appeal, and settlement scenarios that may apply to qualifying drug price increases.

Drug Pricing 59

Drug Pricing 59

Pharmaceutical Commerce

JULY 1, 2025

How Recent Executive Orders Impact the Drug Pricing Landscape Nicholas Saraceno, Editor May 30th 2025 Podcast Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.

Insurance Coverage and Processing 64

Insurance Coverage and Processing Drug Pricing Biosimilars Communication 64

Pharmaceutical Technology

JULY 7, 2025

How will RFK Jr’s American dream for vaccines play out?

Labelling 52

Labelling Packaging Communication Hospitals 52

Pharmaceutical Technology

JUNE 27, 2025

Compounded GLP-1RAs have completely disrupted pricing frameworks for Wegovy and Mounjaro, what happens now? Robert Barrie June 27, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The list price for a month’s supply of 2.4mg Wegovy – the drug’s highest does – is $1,350 in the US, whereas the same dose in the UK costs £175.80

Drug Pricing 59

Drug Pricing Compounding Packaging Communication 59

FDA Law Blog: Biosimilars

APRIL 7, 2025

In a year of major change and outstanding questions, growing scrutiny on patent protection and drug pricing, and uncertainty around global price control measures and the Inflation Reduction Act, understanding the implications of new leadership and emerging mandates is critical.

Drug Pricing 59

Drug Pricing 59

FDA Law Blog: Biosimilars

MARCH 12, 2025

Raimondo Exploring the On-Sale Bar and Applicability of Prior Art Orange Book Delisting Attempts Navigating ODP and Patent Family Dynamics Hyman, Phelps & McNamara, P.C.s

Drug Pricing 59

Drug Pricing 59

FDA Law Blog: Biosimilars

MAY 21, 2025

The announcement comes a little over a month after President Trumps April 15 Executive Order (EO), Lowering Drug Prices by Once Again Putting Americans First.

Drug Pricing 59

Drug Pricing 59

STAT

JULY 10, 2025

Brawl over Eylea gets biosimilar industry’s attention A high-stakes legal fight between Regeneron and Amgen over the blockbuster eye drug Eylea is putting the U.S. patent system under a microscope — and is being closely watched by biosimilar makers. A Phase 1 study in multiple myeloma is underway.

Biosimilars 167

Biosimilars Drug Pricing Drug Development 167

Pharmaceutical Commerce

JUNE 18, 2025

How Recent Executive Orders Impact the Drug Pricing Landscape Nicholas Saraceno, Editor May 30th 2025 Podcast Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access. JAMA Netw Open. 2025;8(6):e2513394.

Drug Pricing 52

Drug Pricing Biosimilars 52

STAT

JULY 10, 2025

And the case is being closely watched by companies that sell biosimilar medicines amid concerns that the U.S. patent system is being gamed in ways that critics say can maintain high prices for medicines.  The treatment, with a list price of nearly $1,900 a shot, is at the heart of a multibillion-dollar product line.

Biosimilars 302

Biosimilars Drug Pricing Drug Development 302

FDA Law Blog: Biosimilars

JUNE 26, 2025

Karst — Earlier this month, the Association for Accessible Medicines and its Biosimilars Council (“AAM”) announced ( here and here ) the release of a report, titled “ Assessment of the Impact of Settlements ,” examining the effects of patent litigation settlements on patient savings and access to generic drugs and biosimilar biological products.

Biosimilars 69

Biosimilars Drug Pricing 69

STAT

MARCH 18, 2024

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies.

Biosimilars 364

Biosimilars Drug Pricing Documentation Pharmaceutical Companies 364

STAT

APRIL 4, 2024

WASHINGTON —  Boehringer Ingelheim is laying off or relocating its sales staff for its Humira biosimilar Cyltezo in a sign of how difficult it’s been to get drug middlemen to adopt less-expensive versions of the blockbuster, the company confirmed. List prices of Humira biosimilars are as much as 85% lower. 

Biosimilars 359

Biosimilars Drug Pricing 359

STAT

APRIL 15, 2024

The number of new prescriptions written for biosimilar versions of the Humira rheumatoid arthritis treatment, one of the best-selling medicines in the U.S., surged to 36% from just 5% during the first week of April, thanks to the expanding reach that CVS Health has over the prescription drug market.

Biosimilars 328

Biosimilars Drug Pricing 328

STAT

APRIL 24, 2024

Two years after biosimilars became available in the U.S., In addition, patients who used biosimilars often did not pay lower out-of-pocket costs than those who were given brand-name biologic medicines. “The whole purpose of biosimilars was to introduce competition into the marketplace and lead the [U.S.]

Biosimilars 333

Biosimilars Medical Schools Hospitals Drug Pricing 333